BioSpace News Archive

Corteva AgriscienceTM has signed a multi-year agreement with Genestack Limited to implement and license the use of Omics Data Manager, Genestack’s multi-omics data catalog, curation and integrative search product.

Culturally-Centric Life Science Company aggressively accelerates the development of the lead platform StarSense and expand the development of a Rubix LS owned clinical trial site for launching clinical trials.

Hospital for Special Surgery (HSS), the world’s leading academic medical center specializing in orthopedics, rheumatology, and related disciplines, has become the first facility in the country to launch a cutting-edge technology for the digitization of pathology slides allowing pathologists to use digital images as primary means of diagnosis

Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the appointment of dermatologist Lawrence Green, MD, FAAD to the position of Scientific Advisory Board (SAB) member.

Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for the eLab® COVID-19 rapid antigen test.

Eden Immersion, the most advanced evolution of whole body cryotherapy treatment, is introducing its three-unit electric product line today.

The fund will create a permanent umbrella to develop initiatives to support researchers of color and increase diversity in cancer research and patient care

Epigenetics-based research tools and services company, Active Motif, Inc., announced that it has launched an end-to-end Hi-C service in partnership with Arima Genomics, Inc. to investigate the three-dimensional folding patterns of the genome, providing researchers with greater access to this powerful technology and advancing their research.

Castlight Health, Inc., a leader in healthcare navigation, will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021, after the market close. At 5:00 p.m. Eastern Time, senior management will host a conference call to review the company’s financial performance.

Continued access to leading innovation from Penn’s Center for Cellular Immunotherapies (CCI) Expanded rights to Penn cell manufacturing and platform technologies Exclusive rights to an additional CAR T-cell therapy product for multiple solid tumors